Floatz logo

Aflibercept

Rectal Cancer

AIO-Studien-gGmbHprotein_peptidePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
73/ 100

Competitive context

114 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

Aflibercept is also rated in:

Metastatic Colorectal CancersDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
metastatic malignant neoplasm in the colonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →